UroGen Pharma Ltd.
URGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | 0.16 | 0.54 | 0.12 |
| FCF Yield | -21.26% | -17.70% | -43.41% | -40.30% |
| EV / EBITDA | -3.70 | -7.25 | -3.24 | -1.87 |
| Quality | ||||
| ROIC | -40.77% | -46.07% | -71.31% | -92.87% |
| Gross Margin | 90.18% | 88.68% | 88.11% | 89.27% |
| Cash Conversion Ratio | 0.76 | 0.75 | 0.80 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.99% | 19.85% | 76.03% | 1,287.13% |
| Free Cash Flow Growth | -26.76% | 12.80% | -2.53% | 20.03% |
| Safety | ||||
| Net Debt / EBITDA | 0.44 | -0.09 | -0.59 | 0.49 |
| Interest Coverage | -7.73 | -4.45 | -9.37 | -5.29 |
| Efficiency | ||||
| Inventory Turnover | 0.96 | 1.65 | 1.77 | 1.07 |
| Cash Conversion Cycle | 11.94 | 35.36 | 14.73 | 21.50 |